Common Veterinary Errors With MDR1 Dogs: A Practitioner's Honest Assessment

I want to be clear about something uncomfortable before I begin this article. The cases I am about to describe involve errors made by veterinarians — by my colleagues, by practitioners in good standing, by clinicians who were trying to help their patients. I have made some of these errors myself earlier in my career. None of these cases involve malicious intent or incompetence in the broad sense. They involve knowledge gaps, assumptions, and system failures that exist throughout our profession.

I am writing this not to condemn my colleagues but because I believe that honest examination of the patterns behind MDR1-related harm is the only way to prevent it. If these cases make practitioners uncomfortable, that discomfort is appropriate and useful. It means the information is landing correctly.

Error Pattern One: Treating the Chart, Not the Breed

The most common error I see is prescribing decisions made from habit rather than from patient-specific assessment. A dog comes in with demodicosis. The practitioner reaches for high-dose ivermectin because it is effective, inexpensive, and has worked in hundreds of previous cases. They note the breed in the chart — Australian Shepherd — but do not pause to connect that breed notation with the MDR1 sensitivity literature.

This is not ignorance. Most veterinarians have heard of MDR1. The problem is that the knowledge does not automatically fire at the right moment in the clinical encounter. The practitioner knows about MDR1 the way they know about many conditions: as a fact in the background that does not always surface when it should.

The fix is systematic rather than educational. MDR1-sensitive breeds should trigger an automatic flag in every clinic management system when a macrocyclic lactone or other P-glycoprotein substrate is being prescribed. The prompt does not need to be elaborate: "This patient is an Australian Shepherd. Has MDR1 status been confirmed before prescribing this medication?" Fifteen seconds. That is all that stands between a routine prescription and a potentially fatal drug reaction.

Error Pattern Two: Incomplete Breed Recognition

Even practitioners who consistently check MDR1 status for the most obviously affected breeds — Collies, Australian Shepherds, Shetland Sheepdogs — often fail to extend the same scrutiny to less obvious candidates. German Shepherds carry the MDR1 mutation at approximately 10% prevalence. Whippets, in their longhaired variety, carry it at remarkable frequency. McNab Shepherds have high rates. Mixed-breed dogs with herding ancestry are affected in unknown but significant proportions.

I have seen German Shepherds receive high-dose ivermectin for mange without MDR1 testing because the practitioner associated the sensitivity primarily with herding breeds and did not categorize German Shepherds in that group. I have seen longhaired Whippets treated as if they had the same drug tolerance as shorthaired Whippets, which have dramatically lower MDR1 prevalence. For breed-specific prevalence data, the MDR1 genetics guide at The Herding Gene provides the most comprehensive compiled statistics available.

The solution is expanding the mental model of which breeds require MDR1 consideration. It is also accepting that in any dog of uncertain or mixed breed background, the default before macrocyclic lactone treatment should be testing, not assumption.

Error Pattern Three: Confusing Heartworm Prevention Doses with Treatment Doses

The dose distinction in MDR1-relevant prescribing cannot be overstated, and it is a source of ongoing errors. Monthly heartworm prevention products containing ivermectin at 6 micrograms per kilogram are generally safe even for MDR1-affected dogs. This safety has led some practitioners to generalize: "ivermectin is fine for this breed." That generalization becomes catastrophically wrong at the doses required for mange treatment.

I have reviewed case notes from practices that administered ivermectin at 300 to 400 micrograms per kilogram to known herding breed dogs for demodicosis, apparently on the basis that the dog had previously tolerated monthly heartworm prevention. The logic is understandable and completely wrong. A dose 50 times higher than a tolerated dose is not simply "more of the same." For an MDR1-affected dog, it may represent the difference between tolerance and fatal toxicity.

Safe alternative protocols for mange treatment in MDR1-sensitive dogs exist and work well. Miltefosine, afoxolaner (NexGard), and certain fluralaner protocols have demonstrated efficacy in demodicosis without the MDR1 risk. There is no clinical need to use ivermectin at high doses in herding breeds when equivalent efficacy is available through safer agents.

Error Pattern Four: Assuming Previous Tolerance Predicts Future Safety

Dogs who tolerate one exposure to a macrocyclic lactone at a particular dose may not tolerate a higher dose, a concurrent medication that inhibits P-glycoprotein, or repeated dosing that leads to accumulation. I have reviewed cases where practitioners noted "no adverse reactions to ivermectin in previous treatments" as justification for escalating to a treatment dose in a dog who had only previously received prevention doses. This reasoning does not hold.

The corollary is equally important: dogs who showed subclinical signs after a previous exposure — unusual lethargy, mild ataxia that resolved spontaneously — may have been tolerating the lower dose at the edge of their individual threshold. Escalating the dose in a dog with that history is moving from a narrow margin of safety to no margin at all.

Error Pattern Five: Inadequate Record Transfer

MDR1 status information that exists in one clinic's records but does not follow the dog to emergency clinics, specialists, and new primary practitioners is nearly useless. I have seen dogs whose primary care veterinarians had MDR1 test results in the file receive inappropriate medications at emergency clinics, boarding facility vets, and specialists because the primary care record was not accessible or was not provided.

Every MDR1-positive test result should trigger a formal record flag, a printed summary in the dog's take-home documentation, and a proactive communication to the owner about where and how to share this information. An MDR1 status that exists only in a single clinic's electronic records has failed at its basic protective function.

Owners bear some responsibility for this — they need to proactively communicate their dog's status. But the initial burden of ensuring they have that information in an accessible, portable format falls on the veterinarian who obtained the test. The guide to emergency clinic communication for MDR1 dogs provides specific protocols that practitioners can share with owners to prevent these handoff failures.

Error Pattern Six: Misidentifying MDR1 Toxicity

Dogs presenting with neurological signs and a history of recent medication administration are sometimes not identified as having MDR1 toxicity because the differential is not considered. The clinical picture — ataxia, mydriasis, CNS depression — is attributed to vestibular disease, encephalitis, or toxin ingestion of a different type. Treatment proceeds along those lines while the actual cause goes unaddressed.

The history question that could prevent this confusion — "Has this dog received any medications, topical treatments, or products recently?" — is standard in emergency triage but must be interpreted through a lens that includes household chemical exposures, products applied to other animals in the household, and access to agricultural areas. The clinical signs guide for ivermectin toxicity provides the pattern recognition information needed to make this diagnosis promptly.

Systemic Solutions Beyond Individual Practitioners

Individual practitioner education matters but is not sufficient. The errors described here are not primarily errors of knowledge — they are errors of system design. Prescribing software that does not alert to breed-specific drug interactions, records systems that do not propagate critical safety flags across facilities, and intake protocols that default to macrocyclic lactones without breed-based risk stratification all create structural conditions for harm.

Veterinary schools have incorporated MDR1 into pharmacology and clinical medicine curricula more thoroughly in recent years, but the practitioner who graduated before that curriculum update may have significant knowledge gaps. Continuing education credits in pharmacogenomics and breed-specific drug sensitivity are increasingly available and should be actively sought by practitioners whose patient populations include herding breeds.

Owners are ultimately the most reliable safety layer. An owner who knows their dog's MDR1 status, communicates it clearly, and advocates persistently at every clinical encounter provides a protection that no system design or educational program can fully replace. The complete MDR1 drug list gives owners the specific information they need to be effective advocates for their dogs at every veterinary encounter.

Moving Forward

The honest accounting I have offered here is uncomfortable precisely because the errors are preventable. We have the genetic tests. We have the knowledge. We have the alternative therapeutic options. What we lack is consistent application of these tools across every clinical encounter where they are relevant. Closing that gap is the ongoing work of veterinary medicine, and it begins with the willingness to examine our error patterns honestly rather than treating each case as an unfortunate anomaly.

My colleagues who have harmed MDR1-sensitive dogs through the patterns described here are not bad veterinarians. They are veterinarians working in a system that does not adequately support the consistent application of specialized knowledge. Changing that system — through better tools, better education, and better owner advocacy — is how we stop these preventable tragedies.